Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CLN-619 (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Carcinoma; Cervical cancer; Endometrial cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Parotid cancer; Salivary gland cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Cullinan Therapeutics

Most Recent Events

  • 27 Feb 2025 According to Cullinan Therapeutics media release, The Company continues enrollment of disease-specific expansion cohorts of its Phase 1 study also it remains on track to report initial data for endometrial and cervical cancers in the second quarter of 2025.
  • 07 Nov 2024 According to Cullinan Oncology media release, company announced they will present dose escalation portion of the Phase 1 study in solid tumors will be presented at the Society for Immunotherapy of Cancer (SITC) in November.
  • 04 Jun 2024 According to Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology, Enrolment in both arms of the dose escalation was complete and based on the findings from dose escalation arms, expansion cohorts will be opened in endometrial cancer and NSCLC.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top